• Individuals with IBD are at an increased risk of developing certain malignancies, both from disease activity as well as certain immunosuppressive medications.
• Withholding some immunosuppressive agents, such as thiopurine, anti-TNF agents, and JAK inhibitors should be considered in patients with active or prior cancers.
• Certain anti-neoplastic regimens, such as hormonal deprivation therapy, immune checkpoint inhibitors (ICIs), and pelvic radiation, can increase the risk of IBD flares during cancer treatment.
• Decisions regarding cancer treatments and IBD therapy should be individualized and made with cooperation between gastroenterologists and oncologists.
